{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["390"],"submitter":["Liu BC"],"pubmed_abstract":["<h4>Objective</h4>To evaluate the efficacy and safety of anrikefon (formerly known as HSK21542), a novel selective peripherally restricted kappa opioid receptor agonist, in patients with chronic kidney disease associated pruritus.<h4>Design</h4>Multicentre, double blind, randomised placebo controlled phase 3 trial.<h4>Setting</h4>50 centres in China, June 2022 to June 2024.<h4>Participants</h4>652 patients with moderate to severe CKD associated pruritus undergoing haemodialysis were screened: 545 were randomly assigned (1:1 ratio) to receive either anrikefon (n=275) or placebo (n=270).<h4>Interventions</h4>Intravenous anrikefon (0.3 μg/kg body weight) or placebo three times weekly for 12 weeks, followed by an optional open label extension phase with anrikefon treatment for 40 weeks.<h4>Mai"],"journal":["BMJ (Clinical research ed.)"],"pagination":["e085208"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12362199"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial."],"pmcid":["PMC12362199"],"pubmed_authors":["Sun FY","Li HB","Wu L","Huang J","Wang CL","Xu YZ","Wan QJ","Wang XH","Guo Q","Zhang P","Wang L","Li GS","Wang XL","Wang XP","Chen W","Xie DQ","Wang Y","Gao BH","Yao L","Wang DG","Zhang XZ","Li YL","Zhang DL","Bai YL","Li Y","Miu LY","Lin HL","Chen WL","Xu Y","Anrikefon-302 study collaborator group","Liu H","Ren W","Long G","Mao N","Du ST","Liu BC","Liu L","Chen BM","Liao B","Li ZL","Chen JH","Wei Y","Zhou LH","Zhou H","Jiang HL","Zhou L","Wang JX","Zhong AM","Yan R","Guan TJ","Li FQ","Lv L","Yi XM","Luo P","Yan TK"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.","description":"<h4>Objective</h4>To evaluate the efficacy and safety of anrikefon (formerly known as HSK21542), a novel selective peripherally restricted kappa opioid receptor agonist, in patients with chronic kidney disease associated pruritus.<h4>Design</h4>Multicentre, double blind, randomised placebo controlled phase 3 trial.<h4>Setting</h4>50 centres in China, June 2022 to June 2024.<h4>Participants</h4>652 patients with moderate to severe CKD associated pruritus undergoing haemodialysis were screened: 545 were randomly assigned (1:1 ratio) to receive either anrikefon (n=275) or placebo (n=270).<h4>Interventions</h4>Intravenous anrikefon (0.3 μg/kg body weight) or placebo three times weekly for 12 weeks, followed by an optional open label extension phase with anrikefon treatment for 40 weeks.<h4>Mai","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-29T15:04:18.453Z","creation":"2026-04-08T05:11:37.658Z"},"accession":"S-EPMC12362199","cross_references":{"pubmed":["40829896"],"doi":["10.1136/bmj-2025-085208"]}}